GRANTS

319 RESULTS

To submit a grant posting, please fill out our web form or download the form so that you can email us at grants@alzforum.org. List the sponsor name, amount, due date, and contact information. This is a free service.

Please Note: We remove grant postings after 6 months. If you would like your listing to be posted longer or taken down sooner, please contact us at grants@alzforum.org.

Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21 - Clinical Trial Not Allowed) (PAR-18-582)

Sponsor: National Institute on Aging

Award: NIA intends to commit $2.5 million in FY 2018 to fund five to eight awards in response to this FOA and its companion R21 FOA PAR-18-581. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: March 29, 2018; June 20, 2018; February 20, 2019; June 20, 2019; February 20, 2020; and June 22, 2020, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 - Clinical Trial Optional) (PAR-18-581)

Sponsor: National Institute on Aging

Award: NIA intends to commit $2.5 million in FY 2018 to fund five to eight awards in response to this FOA and its companion R21 FOA PAR-18-582. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: February 8, 2019; June 7, 2019; February 7, 2020; and June 8, 2020, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

Sponsor: National Institute on Aging

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIH intends to fund an estimate of five to seven awards, corresponding to a total of $10 million, for fiscal year 2018. Future year amounts will depend on annual appropriations.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21 Clinical Trial Optional)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 - Clinical Trial Required)

Sponsor: National Institutes of Health

Award: The NIH anticipates providing $10 million per year to fund an estimated five to seven awards.

Due Date: February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020 , by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 - Clinical Trial Required)

Sponsor: National Institutes of Health

Award: The NIH anticipates providing $10 million per year to fund an estimated five to seven awards.

Due Date: February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020 , by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Testing Lifespan-Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R41/R42 Clinical Trial Not Allowed)

Sponsor: National Institute on Aging

Award: NIA intends to commit $3 million in total costs to fund two to four new awards in FY 2018.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. Note new SBIR/STTR Standard Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Human Cell Biology of Alzheimer's Disease Genetic Variants (R01 - Clinical Trial Not Allowed)

Sponsor: National Institute on Aging

Award: NIH intends to fund an estimate of seven to nin awards, corresponding to a total of $6 million, for fiscal year 2018. Future year amounts will depend on annual appropriations.

Due Date: February 8, 2019; June 7, 2019; October 7, 2019; February 7, 2020; June 7, 2020; and October 7, 2020, by 5 p.m. local time of the applicant organization. Due dates for resubmission and revision applications: July 9, 2018; November 7, 2018; March 7, 2019; July 7, 2019; November 7, 2019; March 7, 2020; July 7, 2020; and November 7, 2020, by 5 p.m. local time of applicant organization

Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01 - Clinical Trial Optional)

Sponsor: National Institute on Aging

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: February 8, 2019; June 8, 2019; February 7, 2020; and June 8, 2020, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates, including new, renewal, resubmission, and revision applications. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

CREATE Bio Development Track: Preclinical and Early Phase Clinical Development for Biologics (U44 SBIR- Clinical Trial Optional)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: February 13, 2019, July 18, 2019, February 13, 2020, and July 20, 2020 , by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

NINDS CREATE Bio Development Track: Preclinical Development for Biotechnology Products and Biologics (U01 - Clinical Trial Optional)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: February 13, 2019, July 18, 2019, February 13, 2020, and July 20, 2020), by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Current Filters

No filters selected

Filter By